secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2025-07-23T23:59:59+00:00
Accession:  0001493152-25-011342
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo plans going-private via reverse split; $3.50/share for fractional shares, 91% premium
--------------------------------------------------------------------------------

- Reverse stock split ratio range 1-for-2,500 to 1-for-7,500; stockholder vote at special meeting Aug 22, 2025.
- Cash payment of $3.50 per pre-split share for fractional shares, representing a 91% premium to July 22 close.
- Holders below 2,500-7,500 pre-split shares will be cashed out; holders above retain one post-split share per minimum.
- Transaction aims to reduce record holders below 300 to terminate SEC registration; board may abandon at any time.
- Company cites high cost of being public as burdensome; will focus on advancing selonabant IV formulation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315225011342/0001493152-25-011342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315225011342/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-011342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer